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Title Commissioning for recovery (NTA, 2010)
Who this document 
is for
• Drug partnerships and their commissioning staff for adult drug 
treatment, reintegration and recovery systems in community and prison 
settings. This is written for commissioning staff based in primary care 
trusts or local authorities. It aims to give practical advice on how local 
commissioners may seek to continually develop effective, evidence-based 
treatment options with a focus on enabling service users to reintegrate into 
society and recover as soon as is practicable.
• This document imposes no new demands or requirements on anyone 
working in the drug treatment system but is intended to help commissioners, 
strategic drug partnerships, prisons and service providers to meet existing 
commitments by providing the latest information and highlighting good 
practice on commissioning in a recovery-based drug treatment system.
What this document 
is about
• Outcome-based commissioning for the drug treatment, reintegration 
and recovery system in drug partnership areas for problem drug users. This 
is based on the four domains measured through the Treatment Outcomes 
Profile (TOP) with the desired goal of achieving reductions in drug use and 
ultimately abstinence in those who can achieve this, reduced offending 
behaviour, an improvement in general health and reintegration with 
education, training, employment, housing and other services. 
• This document draws significantly on the 11 competences required of 
commissioners under the World Class Commissioning approach which is 
compatible with the commissioning principles that apply to drug partnerships 
whether administered in a health or a local authority setting. This approach 
recognises the need for a broad outcomes perspective. This document 
supports the development of a modern, evidence and recovery-based drug 
treatment system covering community and prison settings that needs to be 
delivered in the context of mainstream health reforms which are in keeping 
with the personalisation agenda and the vision set out in ‘High Quality Care 
for All’.
What the purpose of 
this document is
• To draw together current NTA, Department of Health and local authority 
documents that support the development of effective commissioning of the 
drug treatment system in the community and prisons.  
• To assist drug partnerships and their commissioning staff to clearly specify 
the required quality and outcomes, facilitate continuous improvement in 
service design to better meet the needs of the local population, to support 
this work with transparent and fair commissioning and decommissioning 
processes (including demonstrable value for money and clear performance 
management arrangements).  
• Local outcome based commissioning which is based on comprehensive 
needs assessment and the use of outcome data (including any suitable data 
from the analysis of TOP returns), provides an opportunity to develop new 
ways of distributing money and managing for results, energise delivery 
across health and social care, and encourage good performance, innovation 
and learning. Good commissioning will show improved accountability to 
local communities for results, be able to demonstrate value for money and 
good outcomes for service users and their families/communities, be able to 
align and consolidate performance targets and indicators across the health 
and local authority systems and demonstrate accelerated knowledge based 
practice and innovation.
When this document 
can be used
Throughout the commissioning cycle when undertaking needs assessment, 
developing strategy, planning, agreeing contractual arrangements and 
managing the market, performance management and evaluation
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The National Treatment Agency for Substance Misuse (NTA) is a special health authority within the NHS, 
established by government in 2001 to improve the availability, capacity and effectiveness of treatment for 
drug misuse in England.
The NTA works in partnership with national, regional and local agencies to:
Ensure the efficient use of public funding to support effective, appropriate and accessible local services
Promote evidence-based and coordinated practice, by distilling and disseminating best practice
Improve performance by developing standards for treatment, promoting user and carer 
involvement, and expanding and developing the drug treatment workforce
Monitor and develop the effectiveness of treatment.
The NTA has led the successful delivery of Department of Health’s targets to:
Double the number of people in treatment between 1998 and 2008
Increase the percentage of those successfully completing or appropriately continuing treatment year-
on-year.
The NTA is in the frontline of a cross-government drive to reduce the harm caused by drugs. Its task is to 
improve the quality of treatment in order to maximise the benefit to individuals, families and communities. 
Going forward, the NTA will be judged against its ability to deliver better treatment and outcomes for a 
diverse range of drug misusers.
The National Treatment Agency for Substance Misuse,   
6th Floor, Skipton House, 80 London Road, London SE1 6LH  
T: 020 7972 1999 F: 020 7972 1997 E: nta.enquiries@nta-nhs.org.uk
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The 2008 National Drug Strategy states that,  
“The goal of all treatment is for drug users to 
achieve abstinence from their drug – or drugs –  
of dependency”. In order to deliver against all  
the treatment system actions in the drug strategy, 
partnerships will recognize the need to have 
recovery as the bed rock of all commissioning 
decisions.
In practice this will mean that partnerships 
articulate a vision for drug treatment in their area 
that meets the needs of the drug-using population 
– for those currently in treatment and for those as 
yet not engaged with treatment and reintegration 
services.
Partnerships and services will want to articulate 
the ambition of service users and their families 
and that all systems provide options that meet 
these ambitions. This will mean that services stay 
abreast of service-user aspiration – regularly 
checked at individual care plan review stages – and 
seek to maximise opportunities as they present in 
a client’s journey, building on the benefits of being 
in treatment, with a view to recovery steps being 
foremost at all times.
Reintegration options – in both employment and 
housing terms – as outlined by the drug strategy, 
will be an integral part of care planning, with 
partnership efforts focused on harnessing local job 
and housing options as key building blocks to 
maximise recovery.
The drug strategy highlights that partnerships  
will want to build in opportunities in local drug 
treatment systems for families and carers to 
positively impact on the service-user experience  
of treatment and to assist with getting their lives 
back on track.
In order to deliver this challenging agenda, 
partnerships will be aware of the need to pay 
significant attention to how service users exit 
treatment either through community-based 
structured day services, tailored community-based 
abstinence services or via residential 
rehabilitation services. Building on annual needs 
assessments and service-user views, planned exits 
and recovery opportunities are likely to be key 
building blocks in an effective treatment system.
 Foreword
As part of their vision, partnerships may wish to 
consider building links to mutual aid groups into 
all local systems, ensuring that all individual 
services have pathways to mutual aid groups.
Commissioners and joint commissioning groups 
may well wish to consider whether the 
identification of recovery champions at both a 
system and service level would assist in retaining 
the focus of all parties on the recovery agenda. 
Recovery champions could play an important role 
in articulating ambition, championing routes to 
recovery and challenging partnerships and services 
to retain a recovery focus at all stages of a service 
user’s journey.
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Achieving sustained recovery
While the treatment system in England is well 
established and now among the best in the world 
in terms of penetration, prompt access, retention 
and successful discharges, continuing attention 
is required to ensure that the system is balanced 
and offers a range of interventions, including harm 
reduction, abstinence-orientated treatment and 
substitute prescribing for those who need it. 
Further improvements to the foundation of 
good quality care-planned treatment will enable 
personalised treatment to develop and meet 
the needs of the diverse range of drug misusers. 
Improved provision of local systems of support 
and reintegration for misusers and their families 
that prevent risks and enable sustainable lifestyle 
change and wellbeing are also critical to progress.
The 2008 National Drug Strategy recognises the 
improvements required, sets out the Government’s 
vision for the future of drug treatment and focuses 
on the clear tasks ahead:
“The goal of all treatment is for drug users to 
achieve abstinence from their drug – or drugs – 
of dependency. For some, this can be achieved 
immediately, but many others will need a period of 
drug-assisted treatment with prescribed medication 
first. Drug users receiving drug-assisted treatment 
should experience a rapid improvement in their 
overall health and their ability to work, participate 
in training or support their families. They will 
then be supported in trying to achieve abstinence 
as soon as they can. While large numbers are 
entering drug treatment, with most deriving 
significant benefit from it, too many drug users 
relapse, do not complete treatment programmes, 
or stay in treatment for too long before re-
establishing their lives. The challenge for the new 
strategy is to maximise the impact of treatment 
for those who receive it, seizing the opportunity 
treatment provides to reduce the harms caused to 
communities, families and individuals. 
“We will therefore work to develop more 
personalised approaches to treatment services, 
which have the flexibility to respond to individual 
circumstances. We will examine how we can 
best support those leaving and planning to leave 
treatment with packages of support to access 
housing, education, training and employment.” 
Drug misusers, especially those with severe 
dependency, may have many other problems, 
including involvement with the criminal justice 
system, poor educational and employment 
histories, mental health issues, family problems, 
and housing need. Many have poor social and 
personal resources upon which to build a new life. 
Enabling drug misusers to build a lifestyle 
that promotes health and wellbeing, social 
and personal capital, as well as tackling drug 
dependence, requires local partnerships to develop 
comprehensive and multidisciplinary systems. 
Integrating robust pathways with employment 
services is a priority. 
Solid partnership arrangements to support the 
families of drug misusers are also required. 
Developing mutual aid networks may help to 
establish self-help arrangements among recovering 
drug misusers. Local communities and wider 
society also have a responsibility to help drug 
misusers reintegrate into the community: for 
example, by removing any barriers to employment. 
Drug treatment has been proven to reduce drug 
misuse, reduce crime, improve health, and protect 
against blood-borne viruses and overdose.
To achieve recovery focused outcomes, the 
treatment system needs to become more 
responsive to individual needs. Personalised 
packages of care constructed around individuals’ 
aspirations and capabilities need to be developed, 
drawing on good professional care planning, and 
treatment systems need to be responsive to what 
service users want from treatment. 
Most individuals come into treatment wanting 
to become free of their drug of dependency. The 
treatment system needs to achieve an appropriate 
balance, equally comfortable with positively 
routing those who are capable of benefiting 
quickly through abstinence based treatment, and 
retaining those who are not yet able to leave 
treatment supported in services.
There has been much debate about how recovery 
may best be defined as part of this next step in the 
drugs policy. This guide seeks to frame recovery 
in terms of the achievement of the individual 
client’s goals for making positive changes in their 
lives; commonly encompassing whether they have 
gainful employment, appropriate housing and 
functional family relationships. 
 Context
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The commissioning cycle
Quality commissioning is based upon effective 
needs assessment processes and is followed up 
by performance assurance arrangements which 
monitor and evaluate the developments planned 
and commissioned in line with evidenced need.
There is no single approach to the commissioning 
or joint commissioning process, and organisations 
involved will wish to develop strategies that best 
fit their local circumstances. In all instances a 
commissioning cycle framework will be required 
alongside a quality assurance or performance 
management process. These two frameworks or 
processes will mirror each other as well as being 
interdependent on the needs assessment annual 
cycle. All will identify important factors to take into 
account. Monitoring and evaluation are an integral 
component of the process of needs assessment 
and evidence gathered as part of performance 
monitoring and management can then be used as 
the basis for further needs assessment.
Additional support for drug  
partnerships
In order to assist in delivering effective recovery- 
based drug treatment, the NTA works with drug 
partnerships to ensure that:
l local treatment systems seek to maximise the 
number of people who overcome addictions 
and sustain long term recovery
l drug misusers have access to employment, 
education and housing, and that they become 
contributing members of society
l families and communities also receive tangible 
benefits while drug misusers are in treatment, 
and that these benefits are sustained following 
successful treatment
l the increased risk of significant harm and 
neglect among children of drug misusing 
parents receives heightened awareness and 
appropriate action from all those working with 
drug misusers
l the system ensures that safeguarding children 
becomes a central feature of practice.
l local partnerships commission services that 
meet the needs of drug misusers and their 
communities
l those services offer optimal, appropriate 
and accessible evidence-based treatment in 
community, residential and prison settings
l local partnerships promote access to relevant 
mutual aid networks
l management information measures the 
effectiveness of the treatment system
l drug misusers and their carers take part in 
shaping local treatment systems
l drug treatment systems have competent staff, 
good systems of clinical governance, and 
provide good value for money.
Associated guidance
The Department of Health and National Offender 
Management Service are considering publication 
in 2010 of joint guidance on commissioning for 
offenders with drug and/or alcohol problems.
Extensive guidance and support on the 
commissioning of alcohol treatment services is 
provided through the Department of Health’s 
Alcohol Improvement Programme and the 
associated Alcohol Learning Centre at 
www.alcohollearningcentre.org.uk
Commissioning competences checklists
Each section of this document has a checklist 
that commissioning staff may use to stock take 
whether they are currently using the best available 
resources in their area to achieve the best possible 
outcomes in treatment, reintegration and recovery. 
This checklist can be used by drug partnerships, 
and others interested in the partnerships’ overall 
performance, when it is felt a commissioning 
competence assessment would be helpful.
Improvement strategies, materials and tools to assist 
action planning are included in each section or can 











COMMISSIONING CYCLE  
INCORPORATING NEEDS ASSESSMENT
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 Components of effective commissioning
1  Understanding the drug treatment, 
reintegration and recovery challenges 
in the drug partnership area and 
prisons, and setting local goals
1.1  Manage knowledge and undertake 
robust and regular local needs assessments 
that establish a full understanding of current 
and future local drug treatment, recovery and 
reintegration needs and requirements
l Commissioning decisions should be based on 
sound evidence. They capture high-quality and 
timely information from a range of sources, 
and actively seek feedback from relevant 
populations (service users, carers, families, 
clinicians, service providers and strategic 
partners) about services
l By identifying current needs and recognising 
future trends, drug partnerships ensure that 
the services commissioned respond to the 
needs of the whole population, not only now, 
but also in the future. This includes services 
and support for those who wish to follow an 
abstinence based route or who require longer 
term support within the treatment system
l Drug partnerships enable the commissioning 
of a balanced recovery focused treatment 
system with access to community based and 
residential treatment, with ongoing mutual 
aid support that reflects local need, and is 
replicated as appropriate in the prison setting
l Drug partnerships ensure that priority is placed 
on those whose needs are greatest, including 
problem drug users in the criminal justice 
system. To prioritise effectively, commissioning 
staff require a high level of knowledge 
management with associated actuarial and 
analytical skill
l A joint strategic needs assessment (JSNA) 
carried out by primary care trusts and local 
authorities, provides a rich picture of the 
current and future needs of their populations. 
Drug partnerships will be involved in JSNA as 
part of the Local Area Agreement process.  
1.2  Prioritise investment according to 
local needs, service requirements and drug 
partnership strategy/values
l By having a thorough understanding of 
the needs of different sections of the local 
population in the community and prisons, 
commissioning staff, along with the drug 
partnership members, develop a set of clear, 
outcome-focused, strategic priorities and 
investment plans. This requires taking a long-
term view of not only the current in-need 
population, but also of any known changing 
patterns in drug use and any likely future 
changes in needs, so anticipating changes 
in the balance or nature of provision of 
reintegration and recovery initiatives that are 
likely to be optimal over time 
l The drug partnership priorities are formally 
agreed through the annual “drug treatment, 
reintegration and recovery in the community 
and prisons plan” (the Treatment Plan) and 
in many instances are also formally agreed 
through the Local Area Agreement. The 
agreement of the annual plan submitted to the 
NTA includes investment plans to address areas 
of greatest need
l Drug partnerships make confident choices 
about the services that they want to be 
delivered, and acknowledge the impact that 
these choices may have on current services and 
providers  
l Drug partnerships have ambitious but realistic 
goals for the short, medium and long term, 
linked to an outcomes framework and a clear 
plan to continually increase the proportion of 
individuals who leave treatment in a planned 
way and free of their drug(s) of dependency 
l Commissioning staff work with providers to 
ensure that service specifications are focused 
on clinical quality and based on the outcomes 
they want to achieve, and not just on 
processes and inputs.
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Y N Evidence (Y) or Action (N)
Manage knowledge and undertake robust and regular local needs assessments that establish a full understanding of current and future local drug 
treatment, recovery and reintegration needs and requirements
Do you have strategies to further develop and enhance the needs assessment data sets and 
analysis with the drug partnership?
Are you routinely acquiring knowledge and intelligence of the whole community (including 
prisons) through well-defined and rigorous methodologies, including data collection with 
local partners, service providers and other agencies?
Do you identify and use the relevant core data sets required for effective commissioning 
analysis? Are you demonstrating this  use?
Are  you routinely seeking and reporting on research and best practice evidence, including 
clinical evidence that will assist in commissioning and decision making?
Do you share appropriate data with current and potential providers and with relevant 
community and prison groups?
Can you demonstrate that  you have sought and used all relevant data to work with 
communities and clinicians, prioritising strategic commissioning decisions and longer-term 
workforce planning?
Prioritise investment according to local needs, service requirements and drug partnership strategy/values
Do you identify and commission against key priority outcomes and across the key care 
outcome domains identified in current national clinical guidelines, taking into account 
service user experiences, local needs and preferences, risk assessments, national priorities 
and other guidance such as the 2007 UK Clinical Guidelines for drug misuse and the 2007 
NICE drug misuse guidance documents?
Are the selected clinical, health, reintegration and recovery outcomes desired, achievable 
and measurable? Do the outcomes align with partners’ commissioning strategies?
Are you developing short, medium and long term commissioning strategies enabling local 
service design, innovation and development?
Are you identifying and tackling inequalities of health status, access and resource allocation?
Are you routinely using programme budgeting to understand investment against outcomes?
Can you complete comprehensive risk assessments to feed into the wider decision-making 
process and all investment plans?
Are you using financial resources in a planned and sustainable manner and investing for the 
future, including through innovative service design and delivery?
Do you seek and make available valid benchmarking data?
Do you share data with partner organisations, including practice based commissioners, and 
current and potential providers?
Are you monitoring the performance of commissioned strategic health outcomes, using 
TOP clinical outcome measures and measures related to service user experience and public 
engagement?
Materials, guidance and tools
l Undertaking needs assessment. Drug treatment. Recovery and reintegration in the community and prisons. (2009, NTA) 
www.nta.nhs.uk/areas/treatment_planning/treatment_plans_2010_11/needs_assessment_2010_11.pdf 
l Drug treatment, reintegration and recovery in the community and prisons. Guidance notes on completion of 2010/11 
plans for drug partnerships. (2009, NTA) 
www.nta.nhs.uk/areas/treatment_planning/treatment_plans_2010_11/docs/treatment_plan_guidance_%20
2010_11.pdf
l Guidance on joint strategic needs assessment. (2007, Department of Health) 
www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_081267.pdf 
l Commissioning for personalisation: a framework for local authority commissioners. (2008, Department of Health) 
www.dhcarenetworks.org.uk/_library/Resources/Personalisation/Personalisation_advice/Commissioning_for_
Personalisation_-_A_Framework_for_Local_Authority_Commissioners.pdf
l Treatment outcome profile – tools and guidance (2008, NTA) 
www.nta.nhs.uk/areas/outcomes_monitoring/default.aspx
l Key activities in commissioning social care. Parts 1 and 2. (2007, Department of Health) 
www.dhcarenetworks.org.uk/_library/Key_Activities.pdf 
l World class commissioning guidance and materials. (Department of Health) 
www.dh.gov.uk/en/Managingyourorganisation/Commissioning/Worldclasscommissioning/index.htm
l World class commissioning news, information, policy, tools and case studies on commissioning
wcc.networks.nhs.uk
Commissioning competences checklist 
1. Understanding the drug treatment, reintegration and recovery problem 
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2  Local leadership
2.1  Lead and steer the local drug treatment, 
reintegration and recovery agenda in the 
community and prisons
l Drug partnerships actively steer the local drug 
treatment, reintegration and recovery agenda 
in the community and prisons and build their 
reputation within the community and prisons 
so that they are recognised as key leaders of 
the drug treatment system. Drug partnerships 
are  ideally placed to seek and stimulate 
discussion on drug treatment, reintegration 
and recovery matters and to be a primary 
source of credible and timely advice on all 
matters relating to problem drug use and its 
treatment on behalf of the community, prisons 
and other strategic partners
l Drug partnerships work with other parts of 
the Local Strategic Partnership in order to 
improve links with other bodies and agencies, 
particularly around housing and employment 
support, whose active participation and 
engagement is vital to the recovery and 
reintegration agenda
l Drug partnerships and their strategic partners 
contribute to local awareness of the drug 
treatment system and its aims and objectives 
through communication of the availability and 
benefits of drug treatment within the locality, 
and the need upon which the developing 
system is based
l Drug partnerships can consider incorporating 
the role of ‘recovery champion’ to ensure that 
dedicated leadership is provided to enable and 
enhance the continued focus on recovery and 
reintegration across their treatment system.
2.2  Work collaboratively with community 
partners to commission services that optimise 
gains and reduce inequalities in drug 
treatment, reintegration and recovery service 
delivery
l Drug partnerships take into account the wider 
determinants of health and social care, when 
considering how to improve the health and 
well being of their local community and prison 
community in relation to problem drug use.  
To do this effectively, drug partnerships work 
closely and develop a shared ambition with key 
partners including local government, criminal 
justice, healthcare providers, third sector 
organisations and employment bodies. These 
relationships are built up over time, reflecting 
the commitment of partner organisations to 
develop innovative solutions for the whole 
community, including prisons
l Drug partnerships encourage innovation and 
continuous improvement in service design, and 
drive ambitious improvements in health and 
well-being
l Drug partnerships encourage service-level 
‘recovery champions’, who ensure recovery 
and reintegration activities are a central focus 
of service delivery and provide an ongoing 
challenge that ensures service improvement to 
meet developing service user needs
l Drug partnerships have a duty to make 
referrals to the Independent Safeguarding 
Authority where they consider a person has 
caused harm or posed risk of harm to children 
or vulnerable adults; partnerships ensure that 
these arrangements and expectations are 
clearly articulated within their commissioning 
arrangements.
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Y N Evidence (Y) or Action (N)
Lead and steer the local drug treatment, reintegration and recovery agenda in the community and prisons
Are you a primary source of credible, timely and authoritative advice on all matters 
relating to effective drug treatment and associated reintegration and recovery issues?
Do you apply the drug partnership vision to strategic planning and decision making?
Do you work closely with partnership organisations and providers?
Do you ensure that relevant data sharing across all key local strategic partnership 
groups takes place?
Do you engage with and involve the public, service users, their families and carers?
Do you communicate the drug partnership priorities to diverse groups of people?
Do you develop the competences and capabilities of local organisations involved in the 
delivery of the drug treatment system?
Do you effectively manage contracts?
Do you have a clear communications policy? Can you respond effectively to individual, 
organisational and media enquiries regarding the overall drug treatment system?
Work collaboratively with community partners to commission services that optimise gains and reduce inequalities in drug treatment, reintegration and 
recovery service delivery
Does your drug partnership have appropriate partnership agencies engaged to deliver 
the drug treatment, reintegration and recovery agenda (including health, social 
care, criminal justice, local government, and employment) which use defined legal 
agreements and frameworks?
Do you create informal and formal partnering arrangements as appropriate to different 
relationships?
Do you identify key local participants and potential partners (both statutory and non-
statutory) to optimise improvements in outcomes?
Do  you advise and develop local partner commissioning capabilities where there will be 
a direct impact on joint commissioning goals?
Do you share with the local community its ambition for an improved drug treatment, 
reintegration and recovery system?
Do you influence partner commissioning strategies reflecting the drug partnership 
strategy and core values?
Do you  use the skills and knowledge of partners, including clinicians, to inform 
commissioning intentions in all areas of activity?
Do you actively share relevant information so that informed decisions can be made 
across the commissioning community?
Do you monitor and evaluate the effectiveness of the drug partnership?
Materials, guidance and tools 
l Drug treatment, reintegration and recovery in the community and prisons. Guidance notes on completion of 2010/11 
plans for drug partnerships. (2009, appendices 1 and 2, NTA) 
www.nta.nhs.uk/areas/treatment_planning/treatment_plans_2010_11/docs/treatment_plan_guidance_%20
2010_11.pdf
l Planning, commissioning and delivering the training and employment pathway for problem drug users. Developing 
practice for drug partnerships, Jobcentre Plus and drug treatment providers. (2009, NTA) 
www.nta.nhs.uk/publications/documents/planning_commissioning_and_delivering_the_training_and_
employment_pathway_for_problem_drug_users.pdf 
l NHS Institute for Innovation and Improvement. Commissioning to make a bigger difference. A guide for NHS and social 
care commissioners on promoting service innovation. (2008) 
www.institute.nhs.uk/index.php?option=com_joomcart&Itemid=194&main_page=document_product_
info&cPath=67&products_id=394
l DIP engagement tool-kit. (2009, NTA)
www.nta.nhs.uk/areas/criminal_justice/docs/DIP%20toolkit1_972003_feb%202009.pdf
l Integrated Drug Treatment System (IDTS) guidance on roles & responsibilities and governance arrangements. (2009, NTA) 
www.nta.nhs.uk/areas/criminal_justice/docs/IDTS_governance_guidance_final_January_2009.pdf
l Guidance on the protection of vulnerable adults and the implementation of the Vettinand Barring Scheme – Independent 
Safeguarding Authority 
www.dh.gov.uk/en/SocialCare/Deliveringadultsocialcare/Vulnerableadults/index.htm
Commissioning competences checklist 
2. Local leadership 
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3 Choosing interventions
3.1  Engage with service users, their families, 
carers and the public to shape services and 
improve drug treatment, reintegration and 
recovery outcomes
l Drug partnerships act on behalf of communities 
and service users. They are responsible for investing 
funds, and building local trust and legitimacy 
through the process of engagement with their local 
populations. To make commissioning decisions that 
reflect the needs, priorities and aspirations of the 
local population, drug partnerships engage with the 
public, and actively seek the views of drug users, 
their families and carers, and the wider community. 
This relationship is long-term, inclusive, and is 
forged through a sustained effort and commitment 
on the part of commissioners and commissioning 
staff. Decisions are made with a strong mandate 
from the local population and other partners.
3.2  Engage with clinicians to inform strategy 
and drive quality, service design and resource 
utilisation
l Clinical leadership and involvement is a critical and 
integral part of the commissioning process. Drug 
partnerships ensure demonstrable clinical leadership 
and engagement at all stages of the commissioning 
process. Clinicians are best placed to advise and lead 
on issues relating to clinical quality and effectiveness, 
including the interpretation of local TOP data. They 
are the local drug treatment interventions experts, 
and understand clinical needs and have close 
contact with problem drug users
l Drug partnerships ensure the services commissioned 
reflect the needs of the population and are 
delivered in the most personalised, practical and 
effective way possible with clinical standards 
effectively driven by all the strategic partners
l Drug partnerships work in demonstrable ways 
across health, social care and reintegration services 
to drive improvements across the highest priority 
services and meet the most challenging needs 
identified by their strategic plans. This will include a 
crucial role in building and strengthening clinical 
leadership in the strategic commissioning process.
3.3  Ensure a full range of treatment, 
wraparound care and aftercare support 
options are available to aid recovery
l Drug partnerships commission a balanced recovery-
focused treatment system, which incorporates 
the full range of services as specified by the UK 
Clinical Guidelines (2007). This includes attention to 
delivery in relation to safeguarding children and the 
provision of individually tailored care plans delivered 
by competent key workers
l Mutual Aid Groups such as Narcotics Anonymous 
and SMART Recovery provide valuable support 
and positive social networks for individuals who are 
addressing their dependency through treatment. 
Details of how clients can access local recovery 
networks should be made available throughout 
their treatment journey. Services may wish to 
consider more active engagement with local mutual 
aid groups, for example making rooms within the 
treatment service or prisons available for meetings 
during the day, in the evening and at weekends
l Abstinence-based services – including traditional 
residential rehabilitation and newer community-
based rehabilitation models – are an accepted part 
of a balanced treatment system. Commissioners 
need to work closely with service users and with 
providers to commission accessible, joined-up 
community and residential abstinence-oriented 
service provision appropriate for the assessed need, 
with the active engagement of all of their providers 
in utilising these pathways. In some newer models, 
such services may not only support abstinence-
oriented treatment but some may offer parallel 
or integrated support towards reintegration and 
recovery for selected service users who are not 
yet ready for full abstinence-oriented treatments. 
Good referral pathways within the context of 
effective care planning are a prerequisite to enabling 
individuals to overcome their dependency through 
treatment and are vital for effective utilisation of 
such services
l Drug treatment systems invest in abstinence-based 
treatment options and aim to maximise long-term 
effectiveness, spend and prioritisation of aftercare 
support services to supplement mutual aid groups 
and recovery networks
l Adopting a recovery-based drug treatment system 
encompasses an individual’s progress in areas such 
as access to appropriate housing and employment 
and skills. Local treatment providers and 
commissioners need to build appropriate pathways 
and referral protocols with mainstream housing 
providers and Jobcentre Plus, for those service users 
currently undertaking abstinence-oriented and 
maintenance-oriented treatment. Jobcentre Plus 
drug coordinators in every district in England, with 
their remit to build links from employment services 
to the drug treatment system will further support 
this process as well as improved health and well 
being outcomes.
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Y N Evidence (Y) or Action (N)
Engage with service users, their families, carers and the public to shape services and improve treatment, reintegration and recovery outcomes
Can service users, their families and carers, and the public, share their experiences of the 
drug treatment system? Do you use these experiences to inform commissioning?
Do  you have an understanding of the different engagement options, including the 
opportunities, strengths, weaknesses and risks?
Do you invite service users, their families and carers, and the public to respond and comment 
on issues in order to influence commissioning decisions and ensure that services are 
convenient and effective?
Are service users and carers active members of the joint commissioning groups and local 
development meetings?
Do service users, their families, carers and the pubic understand how their views will be 
used?  Do they know which decisions they will be involved in, when decisions will be made, 
and how they can influence the process? Do you publicise ways in which public input has 
influenced decisions?
Do you proactively challenge, and through active dialogue, raise local aspirations to address 
any inequalities in the drug treatment system?
Do you create a trusting relationship with service users, their families and carers and the 
public?  Are you seen as an effective advocate and decision maker on drug treatment 
requirements?
Do you communicate the drug partnership vision, key local priorities and delivery objectives 
to service users, their families and carers, and the public, clarifying the role of the drug 
partnership as a local leader for these services?
Do you respond in an appropriate and timely manner to individual, organisational and media 
enquiries?
Do you undertake assessments and seek feedback to ensure that the public’s experience of 
engagement has been appropriate and not tokenistic?
Engage with clinicians to inform strategy and drive quality, service design and resource utilisation
Do you encourage broad clinical engagement through devolution of commissioning 
decisions?  This includes maximising clinical impact through the development of 
commissioning arrangements (including practice based commissioning where appropriate)?
Do you engage and utilise the skills and knowledge of clinicians to inform commissioning 
intentions in all areas of activity, including setting strategic direction and formulating 
commissioning decisions?
Do you build and support: 
• Broad clinical networks, including across provider boundaries, to facilitate multidisciplinary 
input into pathway and service design? 
• Informed clinical reference groups, ensuring that clinicians and commissioning staff have 
full and timely access to information, enabling local commissioning decisions to be made? 
• Clinical engagement in strategic decision making and suitable quality assurance and clinical 
governance structures?
Do you have robust arrangements for audit of clinical governance across the partnership 
area?
Do you work with clinical colleagues to share best practice concerning the development and 
delivery of effective care pathways?, and do you set clear standards for this to hold clinicians 
to account?
Do you work in partnership with clinicians along care pathways in commissioner and 
provider organisations to facilitate and harness front line innovation and drive continuous 
quality improvement?
Ensure a full range of treatment, wraparound and after-care support options are available to aid recovery
Do you build and support broad networks that include clinicians and those delivering 
reintegration services including housing and employment, to facilitate multidisciplinary input 
into pathway and service design?
Do you build and support informed reference groups that bring together treatment, mutual 
aid and integration delivery staff that ensures they have full and timely access to information, 
enabling local commissioning decisions to be made across the spectrum of services required?
Do you have robust arrangements for audit of treatment services against the criteria for 
evidence based interventions outlined in the 2007 clinical guidelines, including residential 
and community based rehabilitation services, and mutual aid support?
Do you work with clinical and other key stakeholders (housing, employment, etc) to share 
best practice concerning the development and delivery of effective care pathways, and do 
you set clear standards for this to hold them to account?
Do you work in partnership with clinicians and other key stakeholders (housing, employment 
etc.) along care pathways in commissioner and provider organisations to facilitate and 
harness front line innovation and drive continuous quality improvement?
Commissioning competences checklist 
3. Choosing interventions 
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Materials, guidance and tools 
l Drug misuse and dependence: UK guidelines on clinical management. (2007, Department of Health, the Scottish 
Government, Welsh Assembly Government and Northern Ireland Executive)  
www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4009665
l Clinical management of drug dependence in the adult prison setting – Including psychosocial treatment as a core part. 
(2006, Department of Health)  
www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_063059.pdf 
l Clinical governance in drug treatment: a good practice guide for providers and commissioners. (2009, NTA) 
www.nta.nhs.uk/publications/documents/clinicalgovernance0709.pdf
l Commissioning to make a bigger difference. A guide for NHS and social care commissioners on promoting service 
innovation. (2008, NHS Institute for Innovation and Improvement) 
www.institute.nhs.uk/index.php?option=com_joomcart&Itemid=194&main_page=document_product_
info&cPath=67&products_id=394 
l Outcome-based commissioning. (The Centre for Public Innovation)
www.publicinnovation.org.uk/pages/outcome_based_commissioning.html 
l Key activities in commissioning social care. Part 3. (2007, Department of Health) 
www.dhcarenetworks.org.uk/_library/Key_Activities.pdf 
l Supporting and involving carers. A guide for commissioners and providers. (2008, NTA) 
www.nta.nhs.uk/areas/users_and_carers/publications/supporting_and_involving_carers_10.08.pdf 
l Undertaking needs assessment: drug treatment. Recovery and reintegration in the community and prisons. Supplementary 
advice in relation to families and carers. (2009, NTA) 
www.nta.nhs.uk/areas/treatment_planning/treatment_plans_2010_11/supplementary_families_publication_0709.pdf 
l User surveys in relation to tier 2,3 and 4 services. (2007, NTA) 
www.nta.nhs.uk/areas/users_and_carers/user_involvement.aspx 
l Roles and responsibilities of doctors in the provision of treatment for drug and alcohol misusers. (2005, NTA) 
www.nta.nhs.uk/areas/workforce/publications/nta_doctors_roles_and_responsibilities_05.pdf 
l Drugs and Alcohol National Occupational Standards (DANOS) 
www.alcohol-drugs.co.uk/DANOS.htm 
l Workforce development. (2009, NTA)
www.nta.nhs.uk/areas/workforce/default.aspx 
l Harm reduction strategy: guidance and partnership self audit tool to support adult drug treatment plan 2009/10. (NTA) 
www.nta.nhs.uk/areas/treatment_planning/treatment_plans_2009_10/docs/harm_reduction_strategy_
final_2009_10.doc 
l Needle and syringe programmes: providing people who inject drugs with injecting equipment. (2009, NICE) 
guidance.nice.org.uk/PH18/NiceGuidance/pdf/English 
l Care planning practice guide. (2006, NTA) 
www.nta.nhs.uk/publications/documents/nta_care_planning_practice_guide_2006_cpg1.pdf 
l Safeguarding the children of drug misusing parents. (2008, NTA) 
www.nta.nhs.uk/areas/treatment_planning/treatment_plans_2009_10/docs/safeguarding_the_children_of_drug_
misusing_parents_1208.pdf 
l Quick reference guide. Preventing the uptake of smoking by children and young people. (2008, NICE) 
www.nice.org.uk/nicemedia/pdf/PH14quickrefguide.pdf 
l Needs assessment guidance for adult drug treatment. Supplementary guidance for diversity legislation. (2007, NTA) 
www.nta.nhs.uk/areas/treatment_planning/docs/diversity_supplementary_guidance_140807.pdf 
l Equality impact assessment: summary tool and guidance for policy makers. (2008, Department of Health) 
www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_090395.pdf 
l Waiting times guidance. (2006, NTA) 
www.nta.nhs.uk/areas/waiting_times/guidance.aspx 
l Partnership guidance: aligning the Prolific and other Priority Offender (PPO) Programme and the Drug Interventions 
Programme. (DIP). (2007, Home Office) 
www.crimereduction.homeoffice.gov.uk/ppo/PPO_DIP_Alignment_Guidance_v2.pdf
l Planning, commissioning and delivering the training and employment pathway for problem drug users (NTA) 
www.nta.nhs.uk/publications/documents/planning_commissioning_and_delivering_the_training_and_
employment_pathway_for_problem_drug_users.pdf 
l Towards successful treatment completion. A good practice guide.Guidance on unplanned discharges. (NTA) 
www.nta.nhs.uk/publications/documents/completions0909.pdf 
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l Commissioning Tier 4 drug treatment. Guidance for purchasers and commissioners of inpatient treatment and residential 
rehabilitation. (2006, NTA) 
www.nta.nhs.uk/publications/documents/nta_tier_4_commissioning_guidance.pdf 
l Mental health policy implementation guide. Dual diagnosis good practice guide. (2002, Department of Health) 
www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4009058 
l A guide for the management of dual diagnosis for prisons. (2009, Department of Health and Ministry of Justice) 
www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_097694.pdf 
l Routes to recovery part 2. The ITEP manual: delivering psychosocial interventions. (2009)  
www.nta.nhs.uk/publications/documents/itep_routes_to_recovery_part2_180209.pdf 
l Routes to recovery part 4. The BTEI care planning manual: mapping achievable goals. (2009, NTA) 
www.nta.nhs.uk/publications/documents/itep_routes_to_recovery_part4_240309.pdf 
l Routes to recovery part 5. The BTEI exiting treatment manual: mapping achievable goals. (2009, NTA) 
www.nta.nhs.uk/publications/documents/itep_routes_to_recovery_part5_240309.pdf 
l Routes to recovery part 6. The BTEI building motivation manual: enhancing a style of working. (2009, NTA) 
www.nta.nhs.uk/publications/documents/itep_routes_to_recovery_part6_240309.pdf
l Narcotics Anonymous website 
www.ukna.org 
l SMART Recovery UK 
www.smartrecovery.co.uk
l Secular Organizations for Sobriety 
www.sossobriety.org/meetings/countrys.htm 
l Independent Safeguarding Authority
www.isa-gov.org.uk 
l Care Quality Commission (CQC) 
www.cqc.org.uk
l National Institute for Clinical Excellence website has details of technology appraisals, clinical interventions and public 
health interventions guidance for drug treatment  
www.nice.org.uk
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4 Commissioning processes
4.1  Stimulate the market to meet demand 
and secure required clinical, drug treatment, 
reintegration and recovery outcomes
l Drug partnerships have an appropriate choice 
of responsive providers in place to meet the 
range of drug treatment, reintegration and 
recovery needs of the local population in the 
community and prisons
l Employing their knowledge of future priorities, 
needs and community and prison aspirations, 
drug partnerships use their investment choices 
to influence service design, increase choice, and 
drive continuous improvement and innovation
l Drug partnerships have clear strategies for 
dealing with situations where there is a lack 
of provider choice, in particular in areas where 
there is relatively poor penetration of problem 
drug use and limited access to services, 
including residential and community based 
rehabilitation services
l Client choice is an important factor in the 
design and implementation of a balanced 
treatment system, incorporating the full range 
of services as specified in the UK Clinical 
Guidelines (2007).
4.2  Promote improvement in quality and 
outcomes through clinical and provider 
innovation and configuration
l Commissioning staff drive continuous 
improvement in the drug treatment, 
reintegration and recovery system. Their quest 
for knowledge, innovation and best practice 
results in better quality local services and 
significantly improved outcomes using TOP 
data to monitor this when appropriate
l By working with partners to clearly specify 
required quality and outcomes, and influencing 
provision accordingly, commissioning staff 
facilitate continuous improvement in service 
design to better meet the needs of the local 
population. This is supported by transparent 
and fair commissioning and decommissioning 
processes.
4.3  Secure procurement skills that ensure 
robust and viable contracts
l Procurement and contracting processes 
ensure that agreements with providers are 
set out clearly and accurately. By putting in 
place excellent processes, commissioning staff 
facilitate good working relationships with their 
providers, offering protection to service users 
and ensuring value for money
l Contracts specify outcomes wherever possible, 
rather than relying on commissioners to micro 
manage service delivery processes or staffing 
deployment
l Drug partnerships ensure that procurement 
activity is undertaken in line with up to date 
guidance from government departments 
which set out core principles and rules of co-
operation and competition (for example, DH 
guidance on the NHS as preferred provider as 
and when this is published)
l Drug partnerships manage their relationships 
with third sector providers with due regard 
to the Compact and its five underpinning 
principles.
4.4  Ensure efficiency and effectiveness of 
spend
l Drug partnerships make sound financial 
investments to ensure sustainable development 
and value for money
l Drug partnerships ensure that their 
commissioning decisions are sustainable 
and that they are able to secure improved 
outcomes, both now and in the future
l Excellent financial skills and resource 
management enables commissioning staff 
to manage the financial risks involved 
in commissioning and take a proactive 
rather than a reactive approach to financial 
management 
l The financial strategy ensures that the 
commissioning strategy is affordable and set 
within the drug partnership’s overall risk and 
assurance framework.
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Y N Evidence (Y) or Action (N)
Stimulate the market to meet demand and secure required clinical, drug treatment, reintegration and recovery outcomes
Do you map and understand the strengths and weaknesses of current service configuration 
and provision?
Do you have an understanding and knowledge of methods for finding out what matters to 
service users, their families and carers, the public and staff? Are you able to respond to this 
when defining service specifications?
Can  you model and simulate the impact of commissioning decisions and strategies on the 
current configuration of provision?
Can you promote services that encourage timely access, effective retention and discharge, to 
avoid unnecessary unplanned discharges?
Do you have a clear understanding and knowledge of the abilities and role of the third 
sector, and of its ability to provide evidence against service specifications?
Can you translate strategy into short, medium and long term investment requirements, 
allowing providers to align their own investment and planning processes with specified 
requirements?
Are you aware of market trends and behaviours? Can you show knowledge of and act on 
current gaps in the market to provide service users with a choice of local providers?
Can you create incentives where necessary for market entry, including understanding the 
requirements of full cost recovery?
Can you stimulate provider development matched to the requirements and experiences 
accrued from user and community feedback?
Can you specify the realistic time schedules that are needed to encourage and deliver 
innovation and change, providing direct support when required?
Can you develop relationships with potential future providers whose services may be of 
interest and may be relevant to meeting need and demand?
Do you communicate with the market as an investor, not a funder, using and specifying an 
approach based on quality and outcomes?
Promote improvement in quality and outcomes through clinical and provider innovation and configuration
Do you map and understand the strengths and weaknesses of current service innovation, 
quality and outcomes?
Do you maintain an active database of best practice, innovation and service improvement?
Do you analyse local and wider clinical and provider quality and capacity to innovate and 
improve?
Do you share research, clinical and service best practice linked to clear specifications that 
drive innovation and improvement?
Do you communicate with clinicians and providers to challenge established practice and drive 
services that are both convenient and effective?
Do you set stretch targets? Do you challenge providers to come up with innovative ways to 
achieve them?
Do you understand the potential of local community and third sector providers to deliver 
innovative services and increase local social capital?
Do you catalyse change and help to overcome barriers, including recognising and 
challenging traditions and ways of thinking that have outlived their usefulness: Do you 
support providers that constructively break with these?
Do you translate research and knowledge into specific clinical and service reconfiguration, 
improving access, quality and outcomes?
Do you design and negotiate contracts that encourage provider modernisation, continued 
efficiency, quality and innovation?
Are you creating incentives to drive innovation and quality?
Do you secure and maintain relationships with improvement agencies and supplies, 
brokering local knowledge and information networks?
Are you developing relationships with current and potential providers, stimulating whole 
system solutions for drug treatment?
Secure procurement skills that ensure robust and viable contracts
Are you procuring or contracting in proportion to risk and in line with the clinical priorities 
and wider outcomes described in your drug partnership’s commissioning strategy or strategic 
plan?
Are you procuring and contracting in line with relevant health or local authority policies 
including areas such as patient choice, competition principles and rules, NICE guidelines etc.
Do you work with commissioning partners to ensure that your procurement plans are 
consistent with wider local commissioning priorities?
Commissioning competences checklist 
4. Commissioning processes 
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Y N Evidence (Y) or Action (N)
Are you continuously developing your range of procurement techniques and making 
effective use of them?
Do you have a working knowledge of all legal, competition and regulatory requirements 
relevant to your role when tendering?
Are you reflecting the drug partnership vision or strategy through clear and accurate service 
specifications?
Are you assessing business cases according to financial viability, risk, sustainability, and 
alignment with commissioning strategies?
Do you design and negotiate open and fair contracts that provide value for money and are 
enforceable, with agreed performance measures and intervention protocols?
Do contracts cover reasonable time periods, maximising the investment of both the provider 
and the drug partnership funding?
Do  you understand and implement standard national contracts as these become available 
where relevant?
Do you create contingency plans to mitigate against provider failure?
Ensure efficiency and effectiveness of spend
Do you have a thorough understanding of the financial regime in which you operate?
Do you prepare effective financial strategies that identify and take account of trends, key 
risks and potential high impact changes in cost and activity levels?  Do these strategies drive 
the annual budgeting process and support the commissioning strategy?
Are you developing a risk based approach to long term financial planning and budgeting 
that supports relevant and proportionate analysis of financial and activity flows?
Are you routinely using programme budgeting to understand investment against outcomes 
and relative potential shifts in investment opportunities that will optimise local gains in drug 
treatment and increase quality?
Do you use financial resources in a planned and sustainable manner and invest for the 
future?
Do you analyse costs, such as prescribing, and identify areas for improvement?
Do you have a clear understanding of the links between the financial and non-financial 
elements of the drug partnership’s  commissioning strategy?
Are you developing a risk based approach to annual financial management and budgeting?  
Is this supported by the ongoing analysis of financial and activity flows and does it include 
cash management plans to ensure an efficient use of allocated resources?
Does the drug partnership have clear governance structures in place that facilitate and 
ensure active management of all aspects of the partnership’s business and planning 
functions?  Are these transparent, easily understood and public facing?
Do you analyse the activity of the providers through detailed comparisons of expected and 
actual costs and activity?
Do you provide useful, concise and complete financial and activity information to the drug 
partnership to aid decision making, highlighting significant variances where occurring?
Do you have clear and understood processes for dealing with any areas which begin to 
show significant variance from budget during the financial year?  Are these implemented 
effectively by the relevant staff and report to the drug partnership where necessary?
Are you calculating, allocating and reviewing budgets in a fair and transparent manner with 
effective incentive systems? Are you enabling budget leads to fully understand and manage 
their budgets?
Are you developing short, medium and long term strategic financial plans, highlighting areas 
suitable for local service redesign, innovation and development?
Are you working effectively with all service providers by providing financial support and 
information to achieve the most clinically effective and cost effective approaches?
Do you have a well-developed system of governance that ensures financial risks are reported 
and managed at the appropriate level?
Do you have strong financial and ethical values and principles that are publicly expressed and 
underpin the work of all staff and drug partnership members?
Do all drug partnership staff responsible for the management of budgets have access to 
relevant and timely activity and performance data that enables them to operate these 
budgets effectively?
www.nta.nhs.uk	 18Commissioning for recovery
Materials, guidance and tools 




l Part B tendering interpretative communication on the community law applicable to contract awards not or not fully 
subject to the provisions of the Public Procurement Directives (2006/C, 179/02, European Commission) 
eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2006:179:0002:0007:EN:PDF
l Fundamental principles of handling public money. A good practice guide. (2002, NTA) 
www.nta.nhs.uk/publications/documents/nta_handling_money_section6.pdf 
xl Unit costs – guidance on the collection of unit costs for drug misuse treatment 2007/8. (2008,  NTA) 
www.nta.nhs.uk/areas/unit_costs/docs/unit_costs_guidance_part1_revised_aug08.pdf 
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5  Monitoring and evaluation
5.1  Manage systems and work in partnership 
with providers to ensure contract compliance 
and continuous improvements in quality and 
outcomes
l Commissioning staff ensure that providers are 
given the support needed to deliver the highest 
possible quality of service and value for money.  
This involves working closely with partners to 
sustain and improve provision, and engaging in 
constructive performance discussions to ensure 
continuous improvement
l Drug partnerships ensure there are systems 
and processes in place that demonstrate a 
high standard of service and their continual 
improvement, whether in health or social 
care in the public or independent sector. 
Clinical governance arrangements to deliver 
this agenda are subject to regular audit by 
appropriate bodies
l Service specifications comprehensively cover all 
funding that is allocated for drug treatment at 
a local and national level
l By having timely and continuous control 
over contracts, commissioning staff deliver 
better value to service users and taxpayers.  
Commissioning staff use a wide range 
of approaches, including collecting and 
communicating performance data and service 
user feedback, working closely with the NTA 
and other regulators, and intervening when 
necessary to ensure service continuity and 
access
l Drug partnerships ensure that the 
commissioning process is equitable, and 
open to influence from all stakeholders via an 
ongoing dialogue with services users, their 
families and carers, and providers.
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Commissioning competences checklist 
5. Monitoring and evaluation 
Materials, guidance and tools
l World class commissioning assurance handbook. (2008, Department of Health)
www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_085141.pdf
l National metrics to enable measurement and comparison tools 
www.ic.nhs.uk/wccdatapacks
l Auditing drug misuse treatment. (2008, NTA)
www.nta.nhs.uk/publications/documents/auditing_drug_misuse_treatment_1208.pdf
l Regional performance assurance arrangements – adult drug treatment system. (2009, NTA)
www.nta.nhs.uk/areas/treatment_planning/treatment_plans_2009_10/docs/adult_performance_assurance_
guidance_09_10.pdf 
l Recognising, understanding and addressing performance problems in healthcare organisations providing care to NHS 
patients. (2006, Department of Health)
www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4131645 
l Standards for better health. (2004 Department of Health)
www.dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/dh_4086665
Y N Evidence (Y) or Action (N)
Manage systems and work in partnership with providers to ensure contract compliance and continuous improvements in quality and outcomes
Do you monitor provider financial performance, activity and sustainability in accordance 
with contractual agreements?
Are you transparent about your relationships with other organisations that collect, publish, 
assess and regulate providers?
Do you evaluate individual provider performance according to agreed provision 
measurements?
Do you use benchmarking to compare performance between providers? Are you 
communicating performance evaluation findings with providers?
Do you use performance evaluation findings to lead regular and constructive performance 
conversations with providers, working with them to resolve issues?
Do you use agreed dispute procedures for unresolved issues?
Do you recognise an advocacy and expert role in service development for providers? Do 
you invite them to contribute in that role?
Do you disseminate relevant information to allow current providers to innovate and 
develop to meet changing commissioning requirements?
Do you understand the motivations of current providers? Are you fostering an 
environment of shared responsibility and development?
Do you terminate contracts when necessary?
